Equities analysts expect Aclaris Therapeutics Inc (NASDAQ:ACRS) to post earnings per share of ($1.02) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Aclaris Therapeutics’ earnings. The highest EPS estimate is ($0.94) and the lowest is ($1.09). Aclaris Therapeutics reported earnings per share of ($0.56) in the same quarter last year, which would suggest a negative year-over-year growth rate of 82.1%. The company is expected to announce its next earnings results on Tuesday, November 6th.
On average, analysts expect that Aclaris Therapeutics will report full-year earnings of ($4.54) per share for the current year, with EPS estimates ranging from ($4.91) to ($4.30). For the next year, analysts forecast that the company will report earnings of ($3.91) per share, with EPS estimates ranging from ($4.05) to ($3.79). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that follow Aclaris Therapeutics.
Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Friday, August 3rd. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.05) by $0.04. Aclaris Therapeutics had a negative net margin of 1,584.99% and a negative return on equity of 49.45%. The company had revenue of $3.68 million during the quarter, compared to analysts’ expectations of $2.76 million.
ACRS has been the subject of several research reports. Zacks Investment Research upgraded shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a research note on Wednesday, August 8th. BidaskClub upgraded shares of Aclaris Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, May 14th. Finally, Cantor Fitzgerald set a $50.00 target price on shares of Aclaris Therapeutics and gave the company a “buy” rating in a research note on Friday, August 3rd. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $42.60.
In related news, insider Kamil Ali-Jackson sold 5,000 shares of the stock in a transaction dated Tuesday, June 12th. The shares were sold at an average price of $20.00, for a total value of $100,000.00. Following the completion of the transaction, the insider now owns 82,536 shares of the company’s stock, valued at $1,650,720. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Stephen A. Tullman purchased 6,600 shares of the company’s stock in a transaction that occurred on Thursday, August 23rd. The stock was acquired at an average cost of $15.00 per share, with a total value of $99,000.00. Following the transaction, the director now directly owns 170,357 shares of the company’s stock, valued at $2,555,355. The disclosure for this purchase can be found here. 17.00% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the stock. Royal Bank of Canada raised its position in Aclaris Therapeutics by 561.0% in the first quarter. Royal Bank of Canada now owns 6,517 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 5,531 shares in the last quarter. Summit Trail Advisors LLC raised its position in Aclaris Therapeutics by 5,594.3% in the first quarter. Summit Trail Advisors LLC now owns 135,239 shares of the biotechnology company’s stock worth $135,000 after purchasing an additional 132,864 shares in the last quarter. Cubist Systematic Strategies LLC raised its position in Aclaris Therapeutics by 518.4% in the first quarter. Cubist Systematic Strategies LLC now owns 8,361 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 7,009 shares in the last quarter. Bank of Montreal Can acquired a new position in Aclaris Therapeutics in the second quarter worth about $159,000. Finally, Granite Investment Partners LLC acquired a new position in Aclaris Therapeutics in the second quarter worth about $164,000. 99.75% of the stock is owned by hedge funds and other institutional investors.
ACRS stock traded up $0.03 during mid-day trading on Friday, reaching $15.29. 19,189 shares of the stock traded hands, compared to its average volume of 260,537. Aclaris Therapeutics has a 52 week low of $14.11 and a 52 week high of $28.93. The stock has a market capitalization of $495.69 million, a price-to-earnings ratio of -6.10 and a beta of 1.18.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.
Read More: Stock Symbol
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.